Q&A

Get a preview of Chile Connected's anticipated HealthTech panel

Get ready for a fascinating panel. Photo by WebPhotographeer/Getty

The technology and innovation portion of Chile Connected begins next week, and if you haven't already reserved your free spot for the virtual event, you'd be wise to go do it now.

From October 27-29, you can hear from high-level experts and keynote speakers from both Chile and the U.S, as well as network and make new connections that will hopefully lead to a successful partnership.

Josh Sol, the administrative director of Houston Methodist Innovation and Ambulatory Clinical Systems, will be moderating the panel on October 29. The topic is "The Present Future of HealthTech," and will address what COVID-19 means for the future of healthcare technology.

Panelists include Daniela Mendoza, commercial manager for GenoSUR; Alberto Rodríguez-Navarro, founder of Levita Magnetics; and John Dvor, managing director of Miraki Innovation.

InnovationMap recently spoke with Sol about the upcoming event.

InnovationMap: What can U.S. companies gain from participating in this session?

Josh Sol: U.S. companies have the opportunity to gain additional perspectives from other like-minded individuals who are passionate about technology. I've been impressed from the groups and ProChile representatives I have spoken with to date, and I look forward to hearing more about innovation efforts coming from a leading Latin American technology epicenter.

IM: How important are international partnerships in the health tech sector?

JS: Innovation in healthcare technology is coming from all over the globe. Cultural experiences tend to drive creation and innovation. When we collaborate with partners outside of the U.S., we have the opportunity to broaden opportunities and learn from other cultures, and, in turn, we have the potential to apply those insights to what our standard processes are within the U.S. healthcare system.

IM: Personally, why did you feel it important to be involved with Chile Connected?

JS: I have been so impressed by the passion coming from Chile Connected. Discovering new companies doing amazing things in the healthcare technology space continues to fuel my passion for what I do on a day-to-day basis.

IM: What are the key ways businesses can adapt in the pandemic environment?

JS: Businesses should be as nimble as they can — that's a pretty universal lesson most have experienced and we've certainly had first-hand experience in this area as well. At Houston Methodist, our focus is always keeping the patient at the center of everything we do, and we appreciate the collaborative business partners who help us maintain our commitment to our patients, the community, and our clinicians during the pandemic.

Some partners have even pivoted their technology offerings to align with the challenges spurred by COVID. Some areas where we have had to adapt during COVID include ramping up our telemedicine efforts, quickly turning on our virtual ICU, and diversifying the way we communicate with our patients through digital technology.

IM: What do you think is important for start-ups to focus on when trying to grow in this field?

JS: Healthcare technology organizations have many opportunities available to them and must be open to change and the innovations coming from younger start-up companies. As a start-up, it's important to know the problem you are attempting to solve, and to also understand the bigger picture of either the process, patient experience, or clinician experience you are impacting.

Too often, a company will say, "What do you want it to do? It can do anything…" Always come with a solution mindset. Drill down into your offering and what value you have to the organization you're pitching to.

Reserve your free spot for Chile Connected now.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted